References
- THE TRACE STUDY GROUP: The TRAandolopril Cardiac Evaluation (TRACE) Study: Rationale, design, and base-line characteristics of the screened population. Am. J. Cardiol. (1994) 73:44C–50C.
- Detailed methodology of post-AMI prevention study using trandolo-pril and based on echocardiographic (wall motion index) selection of patients.
- AMBROSIONI E, BORGER C, MAGNANI B (ON BEHALF OF THE SMILE STUDY INVESTIGATORS): Survival of Myocar-dial Infarction Long-term Evaluation Study: Rationale, design, organization and outcome. Controlled Clinical Trials (1994) 15:201–210.
- Protocol for post-AMI prevention study using zofenopril and select-ing patients with anterior AM1 not treated with thrombolysis.
- HALL AS, TAN LB AND BALL SG: Inhibition of ACE/kini- nase II, acute myocardial infarction and survivaL Cardiovasc. Res. (1994) 28(2):190–198.
- Detailed review of the background rationale and design of the post-AMI ACE-inhibitor survival studies.
- THE GISSI INVESTIGATORS: GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet(1994) 343:1115–1122.
- Short-term results of the acute administration of lisinopril to relatively unselected patients with suspected myocardial infarction.
- AMBROSIONI E, BORGHI C, MAGNANI B: Early treatment of acute myocardial infarction with angiotensin con-verting enzyme inhibition: safety considerations. SMILE pilot study working party. Am. J. Cardiol. (1991) 68:101D–110D.
- Detailed assessment of the treatment regimen later used in the main SMILE investigation.
- THE GISSI INVESTIGATORS: ACE-inhibitors after myo- cardial infarction [letter]. Lancet (1994) 343:1633–1634.
- Only published report of the differential effects of lisinopril in patients with/without heart failure.
- THE SOLVD INVESTIGATORS: Effect of enalapril on sur-vival in patients with reduced left ventricular ejection fraction and congestive heart failure. New Engl. J. Med. (1991) 325:293–302.
- JOHNSON CI: Franz Volhord Lecture. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular controL J. Hyperten. (1992) 10\(Suppl. 7):S13-S26. This paper reports in vitro differences in the ability of different ACE-inhibitors to prevent binding at both of the enzyme's active sites.
- PENRICH RB, JACKSON B, JOHNSTON CI: Structural con-straints of inhibitors for binding at two active sites on somatic angiotensin converting enzyme. Eur.J. Thelma-col. (1994) 266:201–211.
- Data indicate that two binding sites of plasma ACE are potentially different in their structure and function, suggesting possible differ-ences in substrate specificity.